Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Window period

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    172 result(s) found for: Window period. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2013-005006-66 Sponsor Protocol Number: 2013118 Start Date*: 2014-01-21
    Sponsor Name:Procter and Gamble
    Full Title: A 2-arm, randomised, single - (Investigator) blind, controlled, parallel design study in common cold sufferers experiencing nasal congestion to assess the speed of action of Vicks® VapoRub® (VVR)
    Medical condition: Nasal congestion due to common cold in adults
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-005412-10 Sponsor Protocol Number: OCR002-HE209 Start Date*: 2014-08-25
    Sponsor Name:Ocera Therapeutics Inc
    Full Title: Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (ornithine phenylacetate) in Hospitalized Patients with Cirrhosis and Associated Hyperammonemi...
    Medical condition: Hepatic encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10019660 Hepatic encephalopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) CZ (Completed) AT (Completed) HU (Completed) IT (Completed) DE (Completed) NL (Completed) BE (Completed) DK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-005628-25 Sponsor Protocol Number: Td540 Start Date*: 2016-01-13
    Sponsor Name:Sanofi-Aventis K.K.
    Full Title: Immunogenicity and Safety of The tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (SP306) as a Booster in Japanese Adolescents
    Medical condition: Active immunization against tetanus, diphtheria and pertussis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    18.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    18.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-001651-40 Sponsor Protocol Number: Phaon1 Start Date*: 2020-11-13
    Sponsor Name:palleos healthcare GmbH
    Full Title: An adaptive randomized neoadjuvant two arm trial in triple-negative breast cancer comparing a mono Atezolizumab window followed by a Atezolizumab - CTX therapy with Atezolizumab – CTX therapy (neoM...
    Medical condition: ER negative, PR negative and HER2 negative (triple negative) breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006495-16 Sponsor Protocol Number: PrEPSo Start Date*: 2022-02-25
    Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
    Full Title: Immunogenicity and safety of Sotrovimab (Vir 7831) IV as primary prophylaxis in anti-SARS-CoV-2 vaccine non responders
    Medical condition: Covid 19 Infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084458 COVID-19 prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004226-16 Sponsor Protocol Number: MT-7117-G01 Start Date*: Information not available in EudraCT
    Sponsor Name:Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents with Erythropoietic Protoporphyria or ...
    Medical condition: Erythropoietic Protoporphyria or X-Linked Protoporphyria
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004850 10015289 Erythropoietic protoporphyria LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FI (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004871-11 Sponsor Protocol Number: ULA02 Start Date*: 2019-09-05
    Sponsor Name:Cardiorentis AG
    Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE ESCALATION STUDY OF ULARITIDE FOLLOWED BY A 42-HOUR INFUSION FOR THE TREATMENT OF ACUTE KIDNEY INJURY (AKI) IN PATIENTS POST CARDIAC SURGERY
    Medical condition: Acute kidney injury in patients post cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10069339 Acute kidney injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000631-27 Sponsor Protocol Number: NCT01778842 Start Date*: 2014-01-28
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: PhaRmacodynamic Effect of antiplatelet agents in elderly patients: Standard clopidogrel versus prasugrEl low dose Therapy.
    Medical condition: Patients over 75 years with acute coronary syndrome
    Disease: Version SOC Term Classification Code Term Level
    16.1 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    16.1 10007541 - Cardiac disorders 10071111 Non ST segment elevation acute coronary syndrome LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000543-13 Sponsor Protocol Number: UoL001204 Start Date*: 2016-12-28
    Sponsor Name:University of Liverpool
    Full Title: A window of opportunity study to assess the biological effects of enobosarm in oestrogen receptor positive, androgen receptor positive early breast cancer
    Medical condition: oestrogen receptor, androgen receptor positive early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-001521-41 Sponsor Protocol Number: UoL001304 Start Date*: 2017-09-18
    Sponsor Name:University of Liverpool
    Full Title: A window of opportunity study to assess the biological effects of progesterone in premenopausal ER-positive, PgR-positive early breast cancer
    Medical condition: Premenopausal ER-positive, PgR-positive early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-002077-21 Sponsor Protocol Number: ICR-CTSU/2017/10065 Start Date*: 2019-04-18
    Sponsor Name:The Institute of Cancer Research
    Full Title: PHOENIX Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemoth...
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-000650-11 Sponsor Protocol Number: HEP002 Start Date*: 2014-09-15
    Sponsor Name:Promethera Biosciences
    Full Title: A prospective, open label, multicountry, efficacy and safety study of several infusions of HepaStem in Urea Cycle Disorders pediatric patients.
    Medical condition: The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are seven disorders to be investigated: carbamoylphosphate synthetase I deficiency [CP...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002781-23 Sponsor Protocol Number: DAP-PEDS-07-02 Start Date*: 2015-06-29
    Sponsor Name:Cubist Pharmaceuticals, Inc
    Full Title: An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged Two to Six Years Who are Concurrently Receiving Standard Antibiotic Therapy for Pro...
    Medical condition: Gram-positive Infection
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-003774-16 Sponsor Protocol Number: EIFFEL Start Date*: 2016-06-07
    Sponsor Name:A.R.T.I.C. (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie )
    Full Title: Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride (XOFIGO®) in renal cell carcinoma patients with bone metastases
    Medical condition: Renal cell carcinoma patients with bone metastases, with or without visceral metastases.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001938-11 Sponsor Protocol Number: C22-109-08 Start Date*: 2022-08-18
    Sponsor Name:Pharma Holdings AS
    Full Title: A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 compared to Placebo for nasal decolonisation of Staphylococcus aureus
    Medical condition: Eradication of Staphylococcus aureus from the nose.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004862 10067910 Staphylococcal colonization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000563-41 Sponsor Protocol Number: IMIMFTCL/GH/4 Start Date*: 2014-08-08
    Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar)
    Full Title: Recombinant hGH Biomarkers Discovery
    Medical condition: Healthy volunteers. There is not intended indication.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002533-32 Sponsor Protocol Number: INS1007-201 Start Date*: 2018-03-22
    Sponsor Name:Insmed Incorporated
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety and Tolerability, and Pharmacokinetics of INS1007 Administered Once Daily for 24 We...
    Medical condition: Non-Cystic Fibrosis Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    20.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed) SE (Completed) ES (Completed) NL (Completed) BG (Completed) PL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-003414-36 Sponsor Protocol Number: BX44273 Start Date*: 2023-09-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN LABEL, MULTICENTER EXTENSION STUDY FOR PATIENTS PREVIOSULY ENROLLED IN A GENENTECH AND/OR F. HOFFMAN-LA ROCHE SPONSORED STUDY
    Medical condition: There is no medical condition being investigated. As this is an extension study designed to provide continued treatment for eligible patients who were previously enrolled and treated in a Genentech...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004972-20 Sponsor Protocol Number: PST2744-DM-04-012 Start Date*: 2007-01-18
    Sponsor Name:Sigma-Tau i.f.r. S.p.A.
    Full Title: A Phase II Study to assess the hemodynamic effects of ISTAROXIME, a novel lusinotropic agent, in patients hospitalized with worsening heart failure and a reduced left ventricular systolic function.
    Medical condition: Chronic heart failure and left ventricular systolic dysfunction
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004620-40 Sponsor Protocol Number: BAY 59-7939/11356 Start Date*: 2006-01-26
    Sponsor Name:Bayer HealthCare AS
    Full Title: RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; controlled, double-blind, randomized study of BAY 59-7939 in the prevention of VTE in subjects undergoing elec...
    Medical condition: Prevention of venous thromboembolism
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012108 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) DE (Completed) DK (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 25 14:32:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA